Genoway Stock: price and insider trades · France

genOway is a French biotechnology company listed on Euronext Growth Paris under ticker ALGEN and ISIN FR0004053510. Founded in 1999 and headquartered in Lyon, France, the company designs, develops and commercializes genetically modified preclinical models, mainly mice, rats and cell lines, for pharmaceutical companies, biotech groups and academic institutions. Its core mission is to better “mimic” humans and disease biology in order to improve the predictive power of preclinical research and help drug developers identify the most effective and safest candidates earlier in the R&D process. The group relies on a technological platform supported by exclusive worldwide licenses and advanced gene-editing expertise, enabling it to create knockout, knock-in, humanized, conditional and inducible models tailored to specific scientific needs.

Historically, genOway built its reputation around customized models, but it has progressively expanded into a proprietary catalog of translational off-the-shelf models. Since 2018, this catalog has been particularly focused on immuno-oncology and immunotherapy, two high-growth areas in modern drug discovery. The company also provides bespoke model-generation services for target validation, drug screening, efficacy studies and non-regulatory safety testing. This hybrid model — combining high-value custom projects with recurring catalog products — is central to genOway’s competitive positioning and long-term growth profile.